Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 02 - 14 tags : Cancer save search
ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer
Published: 2022-02-14 (Crawled : 23:00) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 9.91%
H: 12.66%
C: 11.23%
bladder cancer media 100 pons cancer set bladder
LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
lynparza risk prostate cancer state disease one cancer
LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
|
| O: -0.01%
H: 0.09%
C: -0.21%
lynparza risk prostate cancer state disease one cancer biomarkers
Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.32%
H: 1.19%
C: 0.71%
prostate cancer state one therapy cancer
New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.32%
H: 1.19%
C: 0.71%
erleada prostate cancer state response pons cancer
Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: 1.05%
H: 0.29%
C: 0.14%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 1.64%
H: 2.03%
C: 1.71%
padcev bladder cancer therapy results cancer bladder
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
Published: 2022-02-14 (Crawled : 23:00) - prnewswire.com
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 4.23%
H: 6.03%
C: 2.76%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.33%
H: 0.52%
C: -0.47%
lumakras trial 100 cancer pancreatic
BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
BTAI | News | $2.965 4.04% 3.88% 410K
|
Health Technology
|
| O: 0.51%
H: 0.83%
C: -1.24%
bxcl701 phase 2 prostate cancer symposium state trial therapeutics cel asco positive cancer
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
Published: 2022-02-14 (Crawled : 13:00) - biospace.com/
RGBP | $0.7 5.69% 1.5K
|
Manufacturing
|
| O: 12.75%
H: 3.48%
C: -11.3%
biopharma fast track cancer vaccine
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.